Article: US FDA panel approves return of Merck's Vioxx to market

US FDA panel approves return of Merck's Vioxx to market

WASHINGTON, Feb. 18 (Xinhua) -- A US Food and Drug Administration (FDA) advisory panel on Friday approved the safety of the painkiller Vioxx withdrawn by Merck & Co. Inc. and its return to the market.

However, it concluded that Vioxx and its major rivals Pfizer Inc.'s Celebrex and Bextra, which are used to ease arthritis pain, all posed some level of heart risk. The panel voted 17-15 for Vioxx's comeback.

The vote for Celebrex to stay in market was 31-1, and 17-13 with two abstentions for Bextra.

The three prescription medicines, all of a family called COX-2 inhibitors, have been in studies linked to increased risk of heart attack ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!